School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital Unit, Nedlands, WA 6009, Australia.
Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):623-35. doi: 10.1586/egh.10.56.
Nonalcoholic steatohepatitis (NASH) represents the progressive form of nonalcoholic fatty liver disease with greater potential to lead to liver-related morbidity and mortality. Diagnosing NASH mandates more intensive clinical management and consideration for clinical trials. Currently, the diagnosis of NASH requires a liver biopsy, which is invasive, with drawbacks in sampling and interpretation error. Clinical risk factors for NASH include diabetes and the metabolic syndrome; however, these are not sufficiently predictive of the condition by themselves. Routine liver aminotransaminase levels are not reliable; however, novel plasma hepatocyte apoptosis markers, either alone or in combination with clinical risk factors, are potential noninvasive diagnostic tools for the future.
非酒精性脂肪性肝炎（NASH）是一种进行性非酒精性肝病，更有可能导致与肝脏相关的发病率和死亡率。诊断 NASH 需要更强化的临床管理，并考虑进行临床试验。目前，NASH 的诊断需要进行肝活检，这是一种有创的检查，存在采样和解释错误的缺点。NASH 的临床危险因素包括糖尿病和代谢综合征；然而，仅凭这些因素本身并不能充分预测病情。常规的肝转氨酶水平并不可靠；然而，新型血浆肝细胞凋亡标志物，无论是单独使用还是与临床危险因素联合使用，都是未来潜在的非侵入性诊断工具。
